RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024
RxSight announced it will release its Q3 2024 financial results on November 7, 2024, after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Interested parties can join via phone at (888) 596-4144 or (646) 968-2525 using conference code 7406253. A live webcast will be available in listen-only mode through the investor relations website, with a recording accessible afterward.
RxSight ha annunciato che pubblicherà i suoi risultati finanziari per il terzo trimestre del 2024 il 7 novembre 2024, dopo la chiusura del mercato. L'azienda terrà una conference call alle 13:30 PT / 16:30 ET per discutere i risultati. Le parti interessate possono partecipare via telefono al numero (888) 596-4144 o (646) 968-2525 utilizzando il codice conferenza 7406253. Sarà disponibile un webcast in diretta in modalità ascolto tramite il sito web delle relazioni con gli investitori, con una registrazione accessibile successivamente.
RxSight anunció que publicará sus resultados financieros del tercer trimestre de 2024 el 7 de noviembre de 2024, después del cierre del mercado. La compañía llevará a cabo una llamada de conferencia a la 1:30 PM PT / 4:30 PM ET para discutir los resultados. Las partes interesadas pueden unirse por teléfono al (888) 596-4144 o al (646) 968-2525 usando el código de conferencia 7406253. Habrá una transmisión web en vivo disponible en modo solo escucha a través del sitio web de relaciones con inversores, con una grabación accesible posteriormente.
RxSight는 2024년 11월 7일 시장 종료 후 2024년 3분기 재무 결과를 발표할 예정이라고 발표했습니다. 회사는 결과에 대해 논의하기 위해 태평양 표준시 기준 오후 1시 30분/동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜을 개최합니다. 관심 있는 분들은 (888) 596-4144 또는 (646) 968-2525로 전화하여 회의 코드 7406253를 사용하여 참가할 수 있습니다. 투자자 관계 웹사이트를 통해 듣기 전용 모드로 생중계가 제공되며, 이후 녹화된 영상도 이용할 수 있습니다.
RxSight a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le 7 novembre 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique à 13h30 PT / 16h30 ET pour discuter des résultats. Les parties intéressées peuvent rejoindre par téléphone au (888) 596-4144 ou (646) 968-2525 en utilisant le code de conférence 7406253. Un webcast en direct sera disponible en mode écoute seule via le site Web des relations avec les investisseurs, avec un enregistrement accessible par la suite.
RxSight hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 am 7. November 2024 nach Marktschluss veröffentlichen wird. Das Unternehmen wird um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Interessierte Parteien können sich telefonisch unter (888) 596-4144 oder (646) 968-2525 mit dem Konferenzcode 7406253 einwählen. Eine Live-Übertragung wird in nur hörbarem Modus über die Website der Investor Relations verfügbar sein, mit einer später abrufbaren Aufzeichnung.
- None.
- None.
ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To participate in the conference call, please dial (888) 596-4144 or (646) 968-2525, and enter the conference code: 7406253. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+™, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
FAQ
When will RxSight (RXST) report Q3 2024 earnings?
How can I listen to RxSight's (RXST) Q3 2024 earnings call?
What time is RxSight's (RXST) Q3 2024 earnings conference call?
